Skip to content

Study for biomarkers and molecular pathophysiology of depression diversity

Study for biomarkers and molecular pathophysiology of depression diversity - Study for biomarkers and molecular pathophysiology of depression diversity

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000007825
Enrollment
80
Registered
2012-04-24
Start date
2012-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major depressive disorder

Interventions

Comparison of genetic differences among young-onset (onset below 40 aged), middle- or senile-onset (onset above 40 aged) depressive and healthy control patient groups. Comparison of regional brain blo

Sponsors

Gunma University Graduate School of Medicine
Lead Sponsor
Division of neuropsychiatry, department of neuroscience, Yamaguchi university graduate school of medicine
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: This study includes major depressive patients and age- and gender-matched healthy controls, in accordance with following inclusion criteria. 1) Major depressive patients are detected in accordance with Diagnostic and Statistical Manual of Mental Disorder (DSM-IV-TR) 2) Inpatient and out-patient 3) Diagnostic using Mini-International Neuropsychiatric Interview (MINI) 4) Above 50 aged 5) Major Depressive Disorder, Single Episode and multiple episode 6) Major Depressive Disorder with melancholia 7) The patients with above 18 points using Structured Interview Guide for the Hamilton Depression Rating Scale (SIGH-D) 8) The remission period is detected in accordance with below 8 points by Structured Interview Guide for the Hamilton Depression Rating Scale(SIGH-D) 9) Patents with and without drug administration

Exclusion criteria

Exclusion criteria: This study excludes major depressive patients and age- and gender-matched healthy controls, in accordance with following exclusion criteria. 1) The subjects with contraindication for MRI, i.e., heart pacer user 2) The subjects with significant physical illness 3) The pregnant or lactating women 4) The Patents during involuntary admission 5) The Patents during emergency admission 6) The patients, whom medical doctor exclude as impropriety 7) The healthy controls, who has a the first-degree relatives with psychiatric disorders 8) The patients with below 23 points of MMSE

Design outcomes

Primary

MeasureTime frame
Assessments by Near Infra- Red Spectoroscopy, 123I-IMP-SPECT, 3T-Magnetic Resonance Image (MRI), gene and blood sampling to compare among young-onset (onset below 40 aged), middle- or senile-onset (onset above 40 aged) depressive patient and healthy control groups.

Secondary

MeasureTime frame
Assessment by prognosis after treatment, and atherosclerotic factors.

Countries

Japan

Contacts

Public ContactKosuke Narita

Gunma University Graduate School of Medicine Psychiatry and Neuroscience

knarita@gunma-u.ac.jp027-220-8185

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026